Jump to: Authorized Access | Attribution | Authorized Requests

Study Description

This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic strategies for prevention of adverse outcomes in COVID-19 positive inpatients.

  • Study Design:
    • Interventional
  • Study Type:
    • Clinical Trial
    • Controlled Trial
    • Interventional
    • Randomized
    • Randomized Controlled Clinical Trial
  • Total number of consented subjects: 3425
  • Subject Sample Telemetry Report (SSTR)
Authorized Access
Publicly Available Data
  Link to other NCBI resources related to this study
Study Inclusion/Exclusion Criteria

Inclusion Criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • ≥ 18 years of age
  • Hospitalized for COVID-19*
  • Enrolled within 72 hours of hospital admittance or 72 hours of positive COVID test
  • Expected to require hospitalization for > 72 hours
  • (See arm-specific Appendices for additional criteria and details)

*It is strongly recommended to confirm SARS-CoV-2 with a positive microbiological test prior to randomization. At centers where there is delay in confirming the diagnosis, a sufficiently high clinical suspicion is sufficient to proceed with randomization as long as confirmation is expected within 24 hours.

Exclusion Criteria

  • Imminent death
  • Requirement for chronic mechanical ventilation via tracheostomy prior to hospitalization
  • Pregnancy
  • See arm-specific appendices

Selected Publications
Diseases/Traits Related to Study (MeSH terms)
Authorized Data Access Requests
See articles in PMC citing this study accession
Study Attribution
  • Trial Chair
    • Judith Hochman, MD. New York University, New York, NY, USA.